Working with Stakeholders
In cooperation with various stakeholders, the Pharmaceutical Manufacturers Association of Japan (PMAJ) is implementing the following initiatives.
Joint Statement (2012.07)
The Pharmaceutical Manufacturers Association of Japan (JPMA) has issued the attached joint statement with the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and the European Federation of Pharmaceutical Industries and Associations (EFPIA) regarding Internet sales and safe access to medicines.
The IFPMA is joined by The Fondation Chirac, International Council of Nurses (ICN), International Institute of Research Against Counterfeit Medicines (IRACM), Medicines for Malaria Venture, and the European Federation of Pharmaceutical Manufacturers and Associations (EFPIA). Medicines for Malaria Venture (MMV), NCD Alliance, U.S. Pharmacopeial Convention (USP), World Medical Association (WMA) and World Heart Federation. The Pharmaceutical Manufacturers Association of Japan (PMAJ) supports the "Fight the Fakes" campaign in collaboration with the World Heart Federation.
Seminar on Anti-Counterfeit Drugs
On October 24, 2017, the "2017 Anti-Counterfeit Drug Seminar" was held, attended by about 60 participants from 21 pharmaceutical association member companies. The seminar was attended by about 60 participants from 21 pharmaceutical association member companies. In response to the Harvoni case in Japan in 2017, the seminar featured presentations from the Ministry of Health, Labour and Welfare's Surveillance Guidance and Narcotics Control Division, Gilead Sciences, Pharmaceutical Security Institute (PSI), LegitScript, Eisai Inc. of the U.S. The JPMA invited experts in countermeasures against counterfeit pharmaceuticals from the industry, including the Ministry of Health, Labour and Welfare's Monitoring, Guidance and Drug Control Division, Gilead Sciences, Pharmaceutical Security Institute (PSI), LegitScript, and Eisai Inc. Details of this seminar are also introduced in the January 2018 issue of JPMA News Letter.
-
As of December 2023
Participation in educational activities to prevent and combat counterfeit medicines in collaboration with the Pharmaceutical Security Institute (PSI)
Thirty-seven pharmaceutical companies from around the world provide financial support to the Pharmaceutical Protection Institute (PSI) for its anti-counterfeit drug activities (information gathering, coordination with law enforcement, and awareness-raising activities). Astellas Pharma Inc., Chugai Pharmaceutical, Sumitomo Pharma, Eisai, Otsuka Pharmaceutical, and Takeda Pharmaceutical Industries participate as member companies of the Pharmaceutical Association.
Collaboration with INTERPOL (International Criminal Police Organization)
From 2013 to 2015, 29 pharmaceutical companies from around the world provided financial support to INTERPOL's efforts to combat counterfeit medicines, including awareness-raising activities, detection of counterfeit drug manufacturers and distributors, and capacity building for the detection of counterfeit medicines. Astellas, Chugai, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Otsuka Pharmaceutical, Shionogi, and Takeda Pharmaceutical Industries participated as member companies of the pharmaceutical association.